Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species

Abastabar, Mahdi; Al‐Hatmi, Abdullah M. S.; Moghaddam, Mohammad Vafaei; Hoog, G. Sybren de; Haghani, Iman; Âghili, Seyed Reza; Shokohi, Tahereh; Hedayati, Mohammad Taghi; Ghazvini, Roshanak Daie; Kachuei, Reza; Rezaei‐Matehkolaei, Ali; Makimura, Koichi; Meis, Jacques F.; Badali, Hamid

doi:10.1128/aac.00009-18

Cited by 27 publications

(37 citation statements)

References 29 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…34 Similarly, in this study, E483K and P486S substitutions located close to access channel are suggested to behave the same way as L98H substitution of CYP51A of A. fumigatus. In contrast, similar to several previous reports, [35][36][37][38][39] antifungal activity of new imidazoles, luliconazole and lanoconazole, against all A. clavatus isolates was surprisingly superior to amphotericin B, triazoles, caspofungin, and allylamines, suggesting promising candidates for the treatment of different forms of cutaneous aspergillosis caused by this species.…”

supporting

confidence: 88%

Novel Point Mutations in cyp51A and cyp51B Genes Associated with Itraconazole and Posaconazole Resistance in Aspergillus clavatus Isolates

Abastabar

Hosseini

Valadan

et al. 2019

Microbial Drug Resistance

Self Cite

View full text Add to dashboard Cite

Aspergillus clavatus is a common environmental species known to cause occupational allergic disease in grain handlers. We have recently observed azole-resistant isolates of this fungus as a cause of onychomycosis. To further characterize the cause of resistance, the genes encoding 14 a-sterol demethylase enzyme (cyp51A and cyp51B) were characterized and analyzed in 9 ITC-susceptible isolates and 6 isolates with high minimum inhibitory concentrations (MICs) of clinical (nail and sputum) and environmental A. clavatus strains. We found that six isolates with itraconazole MIC >16 mg/L demonstrated nonsynonymous mutations, including V51I, L378P, E483K, and E506G, and synonymous mutations, including F53F, A186A, Q276Q, and H359H. Moreover, P486S was detected in five strains with ITR MIC >16 mg/L. One mutation, F324S, was detected in an isolate with posaconazole MIC >16 mg/L. The effect of E483K and P486S mutations of CYP51A on azole resistance was further investigated using homology modeling and molecular dynamics. We found that E483K and P486S mutations were located near the ligand access channel of CYP51A that could partly lead to narrowing the entry of the ligand access channels. Therefore, we concluded that E483K and P486S mutations may potentially contribute to the limited access of inhibitors to the binding pocket and therefore confer resistance to azole agents.

show abstract

supporting

confidence: 88%

Novel Point Mutations in cyp51A and cyp51B Genes Associated with Itraconazole and Posaconazole Resistance in Aspergillus clavatus Isolates

Abastabar

Hosseini

Valadan

et al. 2019

Microbial Drug Resistance

Self Cite

View full text Add to dashboard Cite

show abstract

“…With the exception of a single isolate of F. verticillioides which had an MIC of 8 g/ml, all had MICs of 16 g/ml (Table 1). These results concur with previously published data on azoles versus Fusarium sp., with MICs of Ն8 for itraconazole (31,32). In conclusion, we found that the in vitro antifungal activity of tavaborole against a panel of different agents of onychomycosis is inferior to those of terbinafine and azoles, except for fluconazole.…”

mentioning

confidence: 60%

Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

Abastabar

Haghani

Shokohi

et al. 2018

Antimicrob Agents Chemother

Self Cite

View full text Add to dashboard Cite

The activity of tavaborole, an FDA-approved antifungal drug, was compared to that of four antifungal agents against 170 clinical fungal isolates originating from patients with onychomycosis. Tavaborole had low activity against all isolates compared to itraconazole, terbinafine, and fluconazole, the principal choices for treatment of onychomycosis. Thus, it appears that tavaborole is not a candidate for the treatment of onychomycosis due to species, species, and dermatophytes.

show abstract

“…All these emerging strains exhibited susceptibility to antifungal drugs, except for A. sydowii , which was inhibited at the concentration of ≥1 μg/mL of efinaconazole and allylamines. On the other hand, our MIC results of two novel imidazoles, namely luliconazole and lanoconazole, against all Aspergillus strains, even against the emerging species, remarkably showed low MIC values of these agents, compared to those of the common antifungal drugs …”

Section: Discussionmentioning

confidence: 84%

“…Fusarium species identification was confirmed by ITS rDNA region and partial sequencing of the translation elongation factor‐1 alpha (TEF ‐1 α) …”

Section: Methodsmentioning

confidence: 99%

Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species)

Haghani

Shams-Ghahfarokhi

Dalimi

et al. 2018

Mycoses

Self Cite

View full text Add to dashboard Cite

Summary Onychomycosis is a common nail problem, accounting for up to 50% of all nail diseases. The aim of the present study was to determine the species distribution based on the restriction fragment length polymorphism and susceptibility patterns of the causative agents of onychomycosis. This cross‐sectional study was conducted on nail samples collected from 257 patients suspected of onychomycosis during 14 months. Fungal isolates were identified by polymerase chain reaction‐restriction fragment length polymorphisms (PCR‐RFLP) with the enzymes Msp I, Mva I, Alw I and sequencing. According to the results, out of the 257 patients participating in the study, onychomycosis was diagnosed in 180 (70.03%) cases, among which 51.1% were caused by non‐dermatophyte moulds (NDMs), 35% by yeast and 10.6% by dermatophytes. Numerous cryptic species recovered from onychomycosis for the first time. In the majority of cases, novel triazoles and imidazoles (ie, efinaconazole, luliconazole and lanoconazole) showed potent activity in comparison with other antifungal agents. The minimum inhibitory concentration (MIC) of luliconazole and lanoconazole ranged within 0.001 to >1 μg/mL and their geometric mean MICs were 0.0154 and 0.0309 μg/mL against all isolates, respectively. It seems that obtained data will be useful to improve the knowledge of researchers, clinicians and dermatologists about onychomycosis distribution, species diversity and adoption of appropriate treatment.

show abstract

Potent Activities of Luliconazole, Lanoconazole, and Eight Comparators against Molecularly Characterized Fusarium Species

Cited by 27 publications

References 29 publications

Novel Point Mutations in cyp51A and cyp51B Genes Associated with Itraconazole and Posaconazole Resistance in Aspergillus clavatus Isolates

Novel Point Mutations in cyp51A and cyp51B Genes Associated with Itraconazole and Posaconazole Resistance in Aspergillus clavatus Isolates

Low In Vitro Antifungal Activity of Tavaborole against Yeasts and Molds from Onychomycosis

Molecular identification and antifungal susceptibility of clinical fungal isolates from onychomycosis (uncommon and emerging species)

Contact Info

Product

Resources

About